US-German immunooncology specialist Immatics Biotechnologies GmbH has licensed two of its TCR-T programs to GlaxoSmithKline for US$50m upfront.
Author Archive for: TG
About Thomas Gabrielczyk
This author has yet to write their bio.Meanwhile lets just say that we are proud Thomas Gabrielczyk contributed a whooping 365 entries.
Entries by Thomas Gabrielczyk
Univercells S.A. cashes in up to 50m from the KKR subsidiary Gamma Bioscience to advance its gene and cell therapy manufacturing platform.
Shortly before a EU health ministers discuss the spread of the Chinese coronavirus, EU diagnostic labs have considered themselves prepared for a possible Sars-CoV-2 epidemic.
PharmaMar and Jazz Pharmaceuticals have received FDA Priority Review of a NDA for lurbinectedin in relapsed SCLC (Small Cell Lung Cancer).
Using a combination of approved diabetes drugs, a Swiss-US research team was able to support the regeneration of insulin-secreting cells in the pancreas.
Researchers report that JAK inhibitors a class of approved anti-inflammatory drugs prevented bone loss in mice with osteoporosis and two patients with rheumatoid arthritis.
Mereo BioPharma has entered into a $5m convertible equity financing with Novartis and a $28m securities purchase agreement with Aspire Capital Fund.
Targeted genome editing using the CRISPR-Cas9 system is easy to use but far from being perfect. Computer calculated modification of CRISPR activity can reduce "off-target effects".
Dutch biotech Azafaros B.V. has closed a 25m Series A financing round.
Infants who show defective immune responses to microbial components are more likely to acquire asthma later in childhood, according to a study of 541 children.